A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Symeonidis, Argiris ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Katodritou, Eirini ^{[6
]}

Hatzimichael, Eleftheria ^{[7
]}

Ntanasis-Stathopoulos, Ioannis ^{[8
]}

Malandrakis, Panagiotis ^{[8
]}

Fotiou, Despina ^{[8
]}

Migkou, Magdalini ^{[8
]}

Theodorakakou, Foteini ^{[8
]}

Spiliopoulou, Vasiliki ^{[8
]}

Syrigou, Rodanthi ^{[8
]}

Eleutherakis-Papaiakovou, Evangelos ^{[2
]}

Manousou, Kyriaki ^{[9
]}

Gavriatopoulou, Maria

Dimopoulos, Meletios A. ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Patras, Sch Med, Hematol Div, Dept Internal Med, Patras, Greece

[4] St Savvas Oncol Hosp, Hematol Dept, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[7] Univ Ioannina, Dept Hematol, Fac Med, Ioannina, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[9] Hlth Data Specialists, Dublin, Ireland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[2] A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
Ocio, Enrique M.
Bringhen, Sara
Oliva, Stefania
Rodriguez-Otero, Paula
Kanagavel, Dheepak
Oprea, Corina
Wei, Vivian
Doroumian, Severine
Martinez-Lopez, Joaquin
BLOOD, 2017, 130
[3] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
Ocio, Enrique M. M.
Bringhen, Sara
Martinez-Lopez, Joaquin
San-Miguel, Jesus
Oliva, Stefania
Rodriguez-Otero, Paula
Le Roux, Nadia
Dong, Yvonne
Doroumian, Severine
Mace, Sandrine
Mateos, Maria-Victoria
HEMASPHERE, 2023, 7 (02):
[4] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Kanagavel, Dheepak
Fitzmaurice, Thomas F.
Wu, Junlong
Martinez Lopez, Joaquin
BLOOD, 2018, 132
[5] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Richardson, Paul G.
Weller, Edie
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raje, Noopur S.
Avigan, David E.
Xie, Wanling
Ghobrial, Irene M.
Schlossman, Robert L.
Mazumder, Amitabha
Munshi, Nikhil C.
Vesole, David H.
Joyce, Robin
Kaufman, Jonathan L.
Doss, Deborah
Warren, Diane L.
Lunde, Laura E.
Kaster, Sarah
DeLaney, Carol
Hideshima, Teru
Mitsiades, Constantine S.
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth C.
BLOOD, 2010, 116 (05) : 679 - 686
[6] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, Lisa B.
Tichy, Diana
Besemer, Britta
Haenel, Mathias
Raab, Marc S.
Mann, Christoph
Munder, Markus
Reinhardt, Hans Christian
Nogai, Axel
Goerner, Martin
Ko, Yon-Dschun
de Wit, Maike
Salwender, Hans
Scheid, Christof
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Einsele, Hermann
Jauch, Anna
Hundemer, Michael
Zago, Manola
Pozek, Ema
Benner, Axel
Bokemeyer, Carsten
Goldschmidt, Hartmut
Weisel, Katja C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
[7] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
Khan, Meaghan L.
Reeder, Craig B.
Kumar, Shaji K.
Lacy, Marthy Q.
Reece, Donna E.
Dispenzieri, Angela
Gertz, Morie A.
Greipp, Phillip
Hayman, Suzanne
Zeldenhurst, Steven
Dingli, David
Lust, John
Russell, Stephen
Laumann, Kristina M.
Mikhael, Joseph R.
Bergsagel, P. Leif
Fonseca, Rafael
Rajkumar, S. Vincent
Stewart, A. Keith
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
[8] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
Dytfeld, Dominik
Dhakal, Binod
Agha, Mounzer
Manier, Salomon
Delforge, Michel
Kuppens, Steven
Afifi, Salma
Deraedt, William
Taraseviciute-Morris, Agne
Schecter, Jordan M.
Gilbert, Jane
Yalniz, Fevzi
Florendo, Erika
Pacaud, Lida
Hungria, Vania
Usmani, Saad Z.
Mateos, Maria-Victoria
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
[9] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob P.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Spillane, Kerry
LaStofka, Brenton
Rosenblatt, Jacalyn
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[10] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
Kumar, S. K.
Flinn, I.
Noga, S. J.
Hari, P.
Rifkin, R.
Callander, N.
Bhandari, M.
Wolf, J. L.
Gasparetto, C.
Krishnan, A.
Grosman, D.
Glass, J.
Sahovic, E. A.
Shi, H.
Webb, I. J.
Richardson, P. G.
Rajkumar, S. V.
LEUKEMIA, 2010, 24 (07) : 1350 - 1356

← 1 2 3 4 5 →